LA
AXDX

Linden Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Linden Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30,450
Closed -$1.78M – 727
2021
Q3 		$1.78M Hold
30,450
– – 0.01% 391
2021
Q2 		$2.45M Hold
30,450
– – 0.01% 429
2021
Q1 		$2.53M Buy
30,450
+4,574
+18% +$464K 0.02% 417
2020
Q4 		$1.96M Buy
+25,876
New +$2.32M 0.01% 325
2020
Q3 		– Sell
-1,061
Closed -$161K – 323
2020
Q2 		$161K Buy
+1,061
New +$105K ﹤0.01% 243

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Linden Advisors's AXDX Position: Q4 2021 in Review

Linden Advisors sold out of Accelerate Diagnostics (AXDX) in Q4 2021, closing a stake of 30,450 shares — an estimated $1.78M sold.

Linden Advisors first reported a position in AXDX in Q2 2020 and held it in 5 quarters. The position peaked at $2.53M in Q1 2021. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2021.

  • Linden Advisors reported no remaining Accelerate Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Linden Advisors sold 30,450 Accelerate Diagnostics shares in Q4 2021, an estimated $1.78M.
  • Linden Advisors first reported a position in Accelerate Diagnostics in Q2 2020 and held it in 5 quarters.
  • Linden Advisors's Accelerate Diagnostics position peaked at $2.53M in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2021.

Based on Linden Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.